15 documents

Read All
22:35 , Jan 30, 2019 |  BC Extra  |  Financial News

Shanghai exchange's proposed innovation board includes preprofit option

The Shanghai Stock Exchange has released draft guidelines for a proposed science and technology innovation board on the exchange that could allow preprofit biopharma companies to list in mainland China. Companies would need to meet...
Read More
01:13 , Dec 11, 2018 |  BC Extra  |  Politics & Policy

China details punishments for IP fraud

China's National Development and Reform Commission published a list of 38 punishments, to be implemented by multiple government institutions including China’s National Medical Products Administration (NMPA), for IP fraud and theft. Punishments from the State...
Read More
19:35 , Aug 31, 2018 |  BC Week In Review  |  Financial News

China GL Capital claims 5% stake in U.K.'s Oxford BioDynamics

Epigenetic biomarker company Oxford BioDynamics plc (LSE:OBD) partnered with GL Capital Group to address demand for healthcare and personalized medicine in China. The Greater China healthcare-focused firm will act as the U.K.-based biotech's lead mainland...
Read More
18:44 , Aug 31, 2018 |  BC Week In Review  |  Financial News

China Biologic spurns acquisition proposal, seeks $590M raise

Plasma products company China Biologic Products Holdings Inc. (NASDAQ:CBPO) said it turned down an acquisition proposal made on Aug. 17, and said it is raising $590 million in a private placement. The Aug. 17 proposal...
Read More
20:15 , Aug 24, 2018 |  BC Extra  |  Company News

China Biologic spurns acquisition proposal, seeks $590M raise

Plasma products company China Biologic Products Holdings Inc. (NASDAQ:CBPO) said it turned down an acquisition proposal made last week, and said it is raising $590 million in a private placement. The Aug. 17 proposal to...
Read More
22:12 , Aug 22, 2018 |  BC Extra  |  Financial News

China's GL Capital claims 5% stake in U.K.'s Oxford BioDynamics

Epigenetic biomarker company Oxford BioDynamics plc (LSE:OBD) partnered with GL Capital Group to address demand for healthcare and personalized medicine in China. The Greater China healthcare-focused firm will act as the U.K.-based biotech's lead mainland...
Read More
21:07 , Aug 20, 2018 |  BC Extra  |  Company News

Consortium including Gao, GL Capital bid to take China Biologic private

A consortium comprising former executive David Gao, GL Capital Group, Bank of China Group Investment Ltd. and CDH Investments proposed on Friday to take plasma products company China Biologic Products Holdings Inc. (NASDAQ:CBPO) private for...
Read More
22:07 , Dec 1, 2017 |  BC Week In Review  |  Company News

SciClone completes going private deal

A consortium of investors led by GL Capital and including Bank of China, CDH, Ascendent Capital Partners and Boying completed its acquisition of SciClone Pharmaceuticals Inc. for $11.18 per share in cash. The deal valued...
Read More
20:21 , Aug 18, 2017 |  BioCentury  |  Finance

Close affiliation

A fresh investment in antibody manufacturing capacity in China will enable both Seattle-based Just Biotherapeutics Inc. and its affiliate Hangzhou Just Biotherapeutics Ltd. to scale up for late stage trials and commercial launches. The U.S....
Read More
16:08 , Aug 11, 2017 |  BC Week In Review  |  Financial News

Just China raises $57M series B

On Aug. 8, biologics company Hangzhou Just Biotherapeutics Ltd. (Hangzhou, China) raised $57 million in a series B round led by Temasek. New investors Taikang, Hangzhou Economic & Technological Development Area, Bank of China and...
Read More